Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease.
DMX-652 is a novel first and best-in-class therapeutic candidate, initially targeting the prevention of acute kidney injury. According to Dimerix, its unique mechanism of action may allow it to be progressed into other indications.
In a statement, Dr. Nina Webster, CEO and managing director of Dimerix, commented, “DMX-652 represents an exciting and differentiated novel compound, and the acquisition of a Phase 2-ready program in acute kidney disease represents an important step in executing our strategy to expand our renal pipeline. This asset is highly complementary to our Phase 3 FSGS program and broadens our development footprint across the kidney disease continuum, from acute injury through to chronic disease.”
